Bromopride

Bromopride

Clinical data
AHFS/Drugs.com	International Drug Names
Routes of administration	Oral, IM, IV
ATC code	A03FA04 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	50 to 75% (oral) 78% (intramuscular)
Protein binding	40%
Metabolism	Hepatic
Elimination half-life	4 to 5 hours
Excretion	Renal, 10 to 14% unchanged
Identifiers
IUPAC name 4-amino-5-bromo-N-[2-(diethylamino)ethyl]-2-methoxybenzamide
CAS Number	4093-35-0 N
PubChem CID	2446
DrugBank	DB09018 N
ChemSpider	2352 Y
UNII	75473V2YZK
KEGG	D07101 Y
ChEMBL	ChEMBL399510 Y
CompTox Dashboard (EPA)	DTXSID0045383
ECHA InfoCard	100.021.675
Chemical and physical data
Formula	C14H22BrN3O2
Molar mass	344.253 g·mol−1
3D model (JSmol)	Interactive image
SMILES Brc1cc(c(OC)cc1N)C(=O)NCCN(CC)CC
InChI InChI=1S/C14H22BrN3O2/c1-4-18(5-2)7-6-17-14(19)10-8-11(15)12(16)9-13(10)20-3/h8-9H,4-7,16H2,1-3H3,(H,17,19) Y Key:GIYAQDDTCWHPPL-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

Bromopride (INN) is a dopamine antagonist with prokinetic properties widely used as an antiemetic, closely related to metoclopramide. It is not available in the United States.

Bromopride appears to be safe and effective for use in pregnancy.^[1]